Described herein are methods and composition for diagnosing and evaluating the treatment of depression using one or more biomarker metabolites for the diagnosis and monitoring treatment efficacy. In one aspect, the biomarker metabolites can be used to screen subjects for the likelihood of developing depression, the diagnosis thereof, monitoring the efficacy of treatment, and evaluating a subject's propensity for responding to treatment.
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
Described herein are methods and composition for diagnosing and evaluating the treatment of depression using one or more biomarker metabolites for the diagnosis and monitoring treatment efficacy. In one aspect, the biomarker metabolites can be used to screen subjects for the likelihood of developing depression, the diagnosis thereof, monitoring the efficacy of treatment, and evaluating a subject's propensity for responding to treatment.
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (USA)
MAYO CLINIC (USA)
Inventeur(s)
Florczyk, Stephen J.
Xu, Kailei
Wang, Zi
Chakrabarti, Ratna
Copland, John, Alton
Abrégé
Disclosed are cell culture scaffolds comprising a scaffold composition comprising chitosan and alginate, hyaluronic acid, or chondroitin sulfate, wherein the scaffold is formed from an aqueous solution comprising greater than 4 wt% chitosan. These scaffolds can be contacted with cells, e.g., patient-derived cancer cells. The scaffolds provide 3D structure allowing appropriate cell function to occur. A scaffold of chitosan and chondroitin sulfate are also disclosed. Scaffold compositions comprising chitosan and alginate, hyaluronic acid, or chondroitin sulfate are also disclosed. Methods of making these scaffolds, e.g., by freeze casting or 3D printing, and using them to evaluate a patient's cancer cell and personalize treatment are also disclosed.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (Inde)
MAYO CLINIC (USA)
Inventeur(s)
Madamsetty, Vijay Sagar
Chaudhuri, Arabinda
Mukhopadhyay, Debabrata
Abrégé
The present invention discloses a Plectin-1 receptor targeting novel cationic KTLLPTPK(SEQ ID NO: 1)-lipopeptide. The present invention further discloses a liposomal formulation comprising the cationic KTLLPTPK(SEQ ID NO: 1)-lipopeptide, at least two co-lipids, a therapeutic agent, and a pharmaceutically acceptable carrier. The present invention also provides a method for regressing established pancreatic tumors comprising administering a therapeutically effective amount of the liposomal formulation with the therapeutic agents in combination with targeted genetic immunization (DNA vaccination) i.e. by immunizing mice with electrostatic complexes (direct in-vivo DC-targeting cationic liposomes) of DNA vaccines encoding mesothelin (p-CMV-MSLN).
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
brevets
